Value Adjusted for Debt and Cash: TuHURA Biosciences, Inc. (HURA)

Brandmark of TuHURA Biosciences (HURA)

The price chart for TuHURA Biosciences, Inc. (HURA) reflects a business valuation that currently stands at 126.29. The company's revenue will be based on the commercialization of personalized vaccines and immune stimulants. The current state is characterized by the depletion of reserves due to testing costs amid zero sales. Meanwhile, skilled management is focusing on developing cutting-edge therapeutic systems while raising funds to complete trials.

HURA TuHURA Biosciences, Inc.: Enterprise Value in the range 11/23/2025 - 10/31/2026

Summary analytical data breakdowns for TuHURA Biosciences (HURA)

- market price and analyst price targets:
Stock Price TuHURA Biosciences Inc.|HURA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value TuHURA Biosciences|HURA - Enterprise Value
- book capitalization information:
Book Value per Share TuHURA Biosciences|HURA - Book Capitalization|Market Cap to Net Assets Ratio tuhurabio.com|HURA - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital TuHURA Biosciences, Inc.|HURA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio TuHURA Biosciences Inc.|HURA - Company Aggregate Debts|Debt to Book Value TuHURA Biosciences|HURA - Company Long-Term Debts|Short-Term Debt TuHURA Biosciences|Intermediate Coverage Ratio tuhurabio.com
- business earnings and investment ratios data:
HURA - Net Income
Summary company analytics:HURA - TuHURA Biosciences, Inc.
Original product of TuHURA Biosciences, Inc.

Defensive assets are selected based on the criterion of undervalued acquisition costs, which is critical for TuHURA Biosciences (HURA) and its developments in the field of anti-cancer vaccines. The current value of 126.29 reflects the real business price, summing market capitalization and debt minus cash, allowing the use of a historical enterprise value chart to identify entry points without the risk of overpaying for the asset.

Who TuHURA Biosciences, Inc. competes with

Enterprise Value BeiGene Ltd. ONC|HALO - Total Company Value|Value Adjusted for Debt and Cash RVMD (Revolution Medicines Corp)|AAPG: Enterprise Value|cgoncology.com (CGON) - Enterprise Value|URGN (UroGen Pharma) - Enterprise Value|Real Price to Acquire Entire Company Bicara Therapeutics Inc (BCAX)|Enterprise Value PSNL|Enterprise Value Erasca Oncology (ERAS)|Total Company Value Delcath Systems, Inc. DCTH|YMAB: Business Value|Aura Biosciences - Enterprise Value|Candel Therapeutics (CADL) - Real Price to Acquire Entire Company|ARAY: Enterprise Value|Total Enterprise Value SELLAS Life Sciences Group (SLS)|Total Company Value Actuate Therapeutics, Inc.|CTOR: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Value Adjusted for Debt and Cash|Enterprise Value WHWK (Aadi Bioscience)|TCRX - Real Price to Acquire Entire Company|CSBR: Real Price to Acquire Entire Company|XBIT - Enterprise Value|cel-sci.com (CVM) - Total Company Value|OS Therapies Inc. - Value Adjusted for Debt and Cash|RADX (Radiopharm Theranostics) - Enterprise Value|Total Enterprise Value Artiva ARTV|Real Price to Acquire Entire Company ANL (Adlai Nortye Ltd.)|Aggregate Business Value VERU|Tempest Therapeutics, Inc. - Real Price to Acquire Entire Company|Enterprise Value Xilio Therapeutics Inc XLO|Enochian BioSciences - Enterprise Value|Value Adjusted for Debt and Cash MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Real Price to Acquire Entire Company|OnKure Therapeutics (OKUR) - Enterprise Value|Total Company Value CytoMed Therapeutics Ltd|CRIS: Value Adjusted for Debt and Cash|Enterprise Value APLM|Enterprise Value Tharimmune Corporation (THAR)|Advanced Biomed - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash GNPX|Calidi Bio - Enterprise Value|SBFM: Total Company Value|XBIO: Enterprise Value|SLRX - Company Buyout Price|Total Company Value Purple Biotech|Total Enterprise Value AON AONC|Total Company Value BeiGene (BGNE)|Company Buyout Price Checkpoint Therapeutics Inc.|Enterprise Value ELEV (Elevation Oncology)|ICAD - Real Price to Acquire Entire Company|Ikena - Enterprise Value|Company Buyout Price notablelabs.com NTBL|VIRX: Enterprise Value|Total Enterprise Value MorphoSys Inc (MOR)|Total Company Value NAYA Bio|Business Value AAPGV (Ascentage)